Denis Schallier

2.1k total citations · 1 hit paper
71 papers, 1.6k citations indexed

About

Denis Schallier is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Denis Schallier has authored 71 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Pulmonary and Respiratory Medicine, 35 papers in Oncology and 14 papers in Molecular Biology. Recurrent topics in Denis Schallier's work include Lung Cancer Treatments and Mutations (23 papers), Lung Cancer Research Studies (14 papers) and Lung Cancer Diagnosis and Treatment (13 papers). Denis Schallier is often cited by papers focused on Lung Cancer Treatments and Mutations (23 papers), Lung Cancer Research Studies (14 papers) and Lung Cancer Diagnosis and Treatment (13 papers). Denis Schallier collaborates with scholars based in Belgium, Netherlands and Germany. Denis Schallier's co-authors include Jacques De Grève, Lore Decoster, Hendrik Everaert, D. Galdermans, Guy Storme, Johan De Mey, Christel Fontaine, Erik Teugels, Marc Meysman and Mark De Ridder and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Denis Schallier

70 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I Study of ⁶⁸Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma

2015 341 citations Marleen Keyaerts, Catarina Xavier et al. Journal of Nuclear Medicine profile →

Peers

Countries citing papers authored by Denis Schallier

Since Specialization

Citations

This map shows the geographic impact of Denis Schallier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Denis Schallier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Denis Schallier more than expected).

Fields of papers citing papers by Denis Schallier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Denis Schallier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Denis Schallier. The network helps show where Denis Schallier may publish in the future.

Co-authorship network of co-authors of Denis Schallier

This figure shows the co-authorship network connecting the top 25 collaborators of Denis Schallier. A scholar is included among the top collaborators of Denis Schallier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Denis Schallier. Denis Schallier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase I Study of [⁶⁸Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I) 2023 ·Journal of Nuclear Medicine ·(unknown), Catarina Xavier, (unknown), Johannes Heemskerk, Nick Devoogdt, Hendrik Everaert, Karine Breckpot, Quentin Lecocq, Lore Decoster, Christel Fontaine, Denis Schallier, Sandrine Aspeslagh, Ilse Vaneycken, Geert Raes, Jo A. Van Ginderachter, Tony Lahoutte, Vicky Caveliers, Marleen Keyaerts	26
2	Geriatric Assessment and Functional Decline in Older Patients with Lung Cancer 2017 ·Lung ·Lore Decoster, Cindy Kenis, Denis Schallier, Johan Vansteenkiste, K. Nackaerts, (unknown), (unknown), Johan Flamaing, J.‐P. Lobelle, Koen Milisen, Jacques De Grève, Hans Wildiers	41
3	Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT) 2016 ·PLoS ONE ·Jacques De Grève, Jan P. van Meerbeeck, Johan Vansteenkiste, Lore Decoster, Anne‐Pascale Meert, Peter Vuylsteke, Christian Focan, Jean-Luc Canon, Yves Humblet, Guy Berchem, Benoît Colinet, (unknown), Lionel Bosquée, Joanna Vermeij, (unknown), Caroline Geers, Denis Schallier, Erik Teugels	16
4	Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients 2014 ·Annals of Oncology ·C. Collen, (unknown), Denis Schallier, Marc Meysman, Michaël Duchateau, Guy Storme, Mark De Ridder	129
5	Expressed wishes and incidence of euthanasia in advanced lung cancer patients 2012 ·European Respiratory Journal ·Koen Pardon, Reginald Deschepper, Robert Vander Stichele, J. Bernheim, Freddy Mortier, Denis Schallier, Paul Germonpré, D. Galdermans, (unknown), Luc Deliëns	9
6	Toxicity and Outcome Results of a Class Solution With Moderately Hypofractionated Radiotherapy in Inoperable Stage III Non–Small Cell Lung Cancer Using Helical Tomotherapy 2010 ·International Journal of Radiation OncologyBiologyPhysics ·Samuel Bral, Michaël Duchateau, Harijati Versmessen, Benedikt Engels, Koen Tournel, Vincent Vinh‐Hung, Mark De Ridder, Denis Schallier, Guy Storme	32
7	Daily Megavoltage Computed Tomography in Lung Cancer Radiotherapy: Correlation Between Volumetric Changes and Local Outcome 2010 ·International Journal of Radiation OncologyBiologyPhysics ·Samuel Bral, Mark De Ridder, Michaël Duchateau, Thierry Gevaert, Benedikt Engels, Denis Schallier, Guy Storme	13
8	Clinical activity of BIBW 2992, an irreversible inhibitor of EGFR and HER2 in adenocarcinoma of the lung with mutations in the kinase domain of HER2neu 2009 ·Journal of Thoracic Oncology ·Jacques De Grève, Lore Decoster, Johan De Mey, Pieter In 'T Veld, Caroline Geers, M. Taton, Mehdi Shahidi, D. Galdermans, Erik Teugels, Denis Schallier	20
9	Toxicity report of a phase 1/2 dose‐escalation study in patients with inoperable, locally advanced nonsmall cell lung cancer with helical tomotherapy and concurrent chemotherapy 2009 ·Cancer ·Samuel Bral, Michaël Duchateau, Harijati Versmessen, (unknown), Benedikt Engels, Mark De Ridder, Koen Tournel, C. Collen, Hendrik Everaert, Denis Schallier, Jacques De Grève, Guy Storme	17
10	Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC) 2008 ·Lung Cancer ·Lore Decoster, Denis Schallier, Hendrik Everaert, Koenraad Nieboer, Marc Meysman, Bart Neyns, Johan De Mey, Jacques De Grève	52
11	Tolerance of adjuvant letrozole outside of clinical trials 2008 ·The Breast ·Christel Fontaine, Ann Meulemans, Manon Huizing, C. Collen, L. Kaufman, Johan De Mey, C. Bourgain, Guy Verfaillie, Jan Lamote, Robert Sacré, Denis Schallier, Bart Neyns, Jan B. Vermorken, Jacques De Grève	41
12	A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC) 2007 ·Lung Cancer ·Denis Schallier, Bart Neyns, Christel Fontaine, (unknown), Johan De Mey, Marc Meysman, Jacques De Grève	8
13	P3-079: Prospective evaluation of first-line tyrosine kinase inhibition with erlotinib in patients with advanced non-small cell lung cancer (NSCLC) harbouring a mutant EGFR gene (FIELT study) 2007 ·Journal of Thoracic Oncology ·Jacques De Grève, Jan P. van Meerbeeck, Johan Vansteenkiste, Denis Schallier, Joanna Vermeij, (unknown), (unknown), (unknown), (unknown), Erik Teugels	2
14	Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study 2006 ·European Respiratory Journal ·(unknown), Leon Bosquée, (unknown), Denis Schallier, (unknown), (unknown), Philippe Collard, Kristiaan Nackaerts, J-L. Canon, (unknown), D. Galdermans, Paul Germonpré, (unknown), Guy Vandenhoven, Jacques De Grève, Johan Vansteenkiste	12
15	Evidence for abrogation of oncogene-induced radioresistance of mammary cancer cells by hexadecylphosphocholine in vitro 1993 ·European Journal of Cancer ·Erik Bruyneel, Guy Storme, Denis Schallier, (unknown), P. Hilgard, M. Mareel	18
16	Carboplatin in combination with etoposide in inoperable non-small-cell lung cancer (NSCLC) 1990 ·Medical Oncology and Tumor Pharmacotherapy ·P. Weynants, Yves Humblet, André Bosly, Denis Schallier, (unknown), F. Majois, M. Beauduin, (unknown), Michel Symann	4
17	Carboplatin in association with etoposide and either adriamycin or epirubicin for untreated small cell lung cancer: A dose escalation study of carboplatin 1989 ·Medical Oncology and Tumor Pharmacotherapy ·Yves Humblet, P. Weynants, André Bosly, F. Majois, (unknown), Charles K. Francis, M. Beauduin, J. H. Machiels, (unknown), Luc Delaunois, Daniel Rodenstein, Chantal Doyen, J Longueville, (unknown), Denis Schallier, J Prignot, Michel Symann	14
18	Molecular Biology of Minimal Invasion 1988 ·Recent results in cancer research ·Marcus Mareel, Frans van Roy, (unknown), Jan G.M. Bolscher, Denis Schallier, (unknown)	3
19	Is adjuvant treatment with vinblastine effective in reducing the occurrence of distant metastasis in limited squamous cell lung cancer? A randomized study 1988 ·Clinical & Experimental Metastasis ·Denis Schallier, Wilfried J. De Neve, Jacques De Grève, (unknown), (unknown), (unknown), Guy Storme	6
20	Periventricular Metastases of a Primary Intracranial α-Fetoprotein-Producing Germ Cell Tumor 1986 ·European Neurology ·M. Bruyland, Ove A. Peters, Denis Schallier, Eva De Smedt, A. Goossens, (unknown), Guy Ebinger	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact